Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis.

In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union.

• Analyses from the Phase 3 RESPONSE trial ( NCT04620733) will evaluate efficacy and safety in participants with risk factors for disease progress, including elevated liver stiffness and metabolic syndrome.
• Interim data from the Phase 3 ASSURE study ( NCT03301506) will assess the relationship between biochemical response and liver stiffness trends over 36 months, including outcomes in individuals with alkaline phosphatase (ALP) levels between 1 to 1.67x the upper limit of normal (ULN).

Together these data provide a multidimensional view of Livdelzi’s efficacy, safety and durability across a broad PBC population. Livdelzi is a first‑in‑class delpar (selective PPAR‑delta agonist) indicated for the treatment of PBC to be used in combination with ursodeoxycholic acid (UDCA) for those with an inadequate response to UDCA, or as monotherapy for patients unable to tolerate UDCA.

“Primary biliary cholangitis is a chronic, progressive disease where reducing disease activity is critical to improving long‑term outcomes. Minimizing impact on quality of life is also key for people living with PBC,” said Swati Tole, MD, MS, Senior Vice President, Clinical Development, Inflammation at Gilead Sciences. “At EASL, we are sharing data that further define Livdelzi’s potential to address both disease activity and symptoms such as pruritus.”

Advancements in Hepatitis Delta Virus

Presentations will also focus on hepatitis delta virus (HDV), a severe co‑infection in people with chronic hepatitis B. The program will include several analyses evaluating investigational bulevirtide, a first‑in‑class entry inhibitor, in diverse HDV patient populations, reflecting continued efforts to better understand HDV disease management and treatment approaches.

“People living with HDV face a severe disease with limited treatment options. These analyses highlight the breadth of ongoing research and Gilead’s continued leadership in advancing the understanding of HDV, including efforts to evaluate Hepcludex across diverse patient populations,” said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology at Gilead Sciences. “We remain committed to continuously building on emerging evidence to help improve how this disease is managed over time, and we encourage clinicians to engage with evolving data to help inform care for people living with HDV.”

Analyses from Phase 2 and Phase 3 studies, including MYR301 (NCT03852719) and MYR204 (NCT03852433) will evaluate clinical, virologic, and biochemical outcomes, as well as safety and tolerability, through 96 weeks across HDV subgroups.

An additional study uses a machine‑learning model to identify risk factors for progression to advanced liver disease in adults with HDV infection in the United States.